


duration of responses suggest they were limited by toxicities. Thus, there is a need for FGFR2-selective inhibitor compounds and methods for treating cancers and other disorders with these compounds. (For reviews of pan-FGFR1-3 inhibitors and clinical responses, see I. S. Babina and N.C. Turner, *Nat. Rev. Cancer* 2017, 17:318-332; M. Katoh, *Nat. Rev. Clin. Oncol.* 2019, 16:105-122; and references cited therein.).


SUMMARY

[0003a] In an aspect of the present disclosure, there is provided a compound, which is



or a pharmaceutically acceptable salt thereof.

[0003b] In another aspect of the present disclosure, there is provided a pharmaceutical composition comprising a compound:




, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0003c] In a further aspect of the present disclosure, there is provided a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition disclosed herein, for use in therapy.

[0003d] In another aspect of the present disclosure, there is provided a use of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition disclosed herein, in the manufacture of a medicament for treating a disorder in a subject, wherein the disorder is bile duct cancer, liver cancer, breast cancer, prostate cancer, lung cancer, thyroid cancer, gastric cancer, ovarian cancer, rectal cancer, endometrial cancer, or urothelial cancer.


[0004] In some examples, the present disclosure provides a compound of formula I-1:



I-1

or a pharmaceutically acceptable salt thereof, wherein each of Cy^A , Cy^6 , L^6 , R^5 , and R^W is as defined in examples and classes and subclasses herein.

[0005] In some examples, the present disclosure provides a compound of formula I:



I


or a pharmaceutically acceptable salt thereof, wherein each of Cy^6 , L^6 , R^5 , R^7 , and R^W is as defined in examples and classes and subclasses herein.

[0006] In some examples, the present disclosure provides a pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or diluent. In some examples, the present disclosure provides a pharmaceutical composition comprising a compound of the present disclosure, for example, a compound of formula I-1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or diluent.

[0007] In some examples, the present disclosure provides a method of treating a FGFR-mediated disorder comprising administering to a patient in need thereof a compound of formula I, or composition comprising said compound. In some examples, the present


What is claimed is:

1. A compound, which is



or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound:



, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 2, for use in therapy.

4. Use of the compound of claim 1, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 2, in the manufacture of a medicament for treating a disorder in a subject, wherein the disorder is bile duct cancer, liver cancer, breast cancer, prostate cancer, lung cancer, thyroid cancer, gastric cancer, ovarian cancer, rectal cancer, endometrial cancer, or urothelial cancer.

5. The use of claim 4, wherein the disorder is bile duct cancer.

6. The use of claim 5, wherein the bile duct cancer is intrahepatic cholangiocarcinoma.

7. The use of claim 4, wherein the disorder is liver cancer.
8. The use of claim 7, wherein the liver cancer is hepatocellular carcinoma.
9. The use of claim 4, wherein the disorder is lung cancer.
10. The use of claim 9, wherein the lung cancer is lung squamous cell carcinoma or non-small cell lung cancer.